Skip to main content
. 2013 Oct 27;93(1):71–80. doi: 10.1007/s00277-013-1937-4

Table 1.

Patients and treatment arms

Age groups, years 16–29 30–44 45–59 At least 60
All patients, n 120 383 495 526
 Imatinib (400 mg), n (%) 25 (21) 93 (24) 131 (26) 147 (28)
 Imatinib (400 mg + IFN-α), n (%) 39 (32) 102 (27) 139 (28) 145 (27)
 Imatinib (400 mg + cytarabine), n (%) 13 (11) 39 (10) 53 (11) 53 (10)
 Imatinib (400 mg after IFN-α failure), n (%) 8 (7) 35 (9) 37 (7) 48 (9)
 Imatinib (800 mg), n (%) 35 (29) 114 (29) 135 (27) 133 (25)

N number of patients, IFN-α interferon